Overview
About mir|detect
Welcome to mir|detect GmbH – shaping the future of molecular diagnostics.
At mir|detect, we are committed to revolutionizing molecular diagnostics with innovative solutions designed for laboratories and healthcare professionals around the world. Based in Bremerhaven, our mission is to deliver cutting-edge tools that empower better patient care.
Our flagship product, the M371-Test, is a groundbreaking diagnostic tool for testicular cancer. With unmatched accuracy and efficiency, it supports both primary diagnosis and follow-up monitoring. By reducing overtreatment and minimizing the long-term toxicity of chemotherapy and diagnostic irradiation, the M371-Test is making a meaningful impact on patient outcomes. In 2024, we achieved IVDR certification for the M371-Test, a milestone that highlights our dedication to the highest standards of quality, safety, and compliance within the European diagnostics market.
At the core of our innovation is our proprietary pre-amplification technology, which enhances the performance of diagnostic nucleic acid markers. This versatile platform enables the development of assays for novel biomarkers or improves existing diagnostics. It is also available for licensing, providing partners with the tools to create their own groundbreaking diagnostic solutions.
Whether you are a diagnostic laboratory seeking our advanced tools, a medical professional exploring new possibilities, or a partner looking to leverage our technology, we’re here to collaborate with you.
Get in touch with us to learn more about our products and how we can support your diagnostic needs. Send us a message here on LinkedIn or visit our website at www.mirdetect.de.
At mir|detect, we are committed to revolutionizing molecular diagnostics with innovative solutions designed for laboratories and healthcare professionals around the world. Based in Bremerhaven, our mission is to deliver cutting-edge tools that empower better patient care.
Our flagship product, the M371-Test, is a groundbreaking diagnostic tool for testicular cancer. With unmatched accuracy and efficiency, it supports both primary diagnosis and follow-up monitoring. By reducing overtreatment and minimizing the long-term toxicity of chemotherapy and diagnostic irradiation, the M371-Test is making a meaningful impact on patient outcomes. In 2024, we achieved IVDR certification for the M371-Test, a milestone that highlights our dedication to the highest standards of quality, safety, and compliance within the European diagnostics market.
At the core of our innovation is our proprietary pre-amplification technology, which enhances the performance of diagnostic nucleic acid markers. This versatile platform enables the development of assays for novel biomarkers or improves existing diagnostics. It is also available for licensing, providing partners with the tools to create their own groundbreaking diagnostic solutions.
Whether you are a diagnostic laboratory seeking our advanced tools, a medical professional exploring new possibilities, or a partner looking to leverage our technology, we’re here to collaborate with you.
Get in touch with us to learn more about our products and how we can support your diagnostic needs. Send us a message here on LinkedIn or visit our website at www.mirdetect.de.